Neoadjuvant Taxane/Carboplatin/Trastuzumab/Pertuzumab in Patients with HER2-Positive Early or Locally-Advanced Breast Cancer: A Retrospective, Single-Center, Observational Study
Indian Journal of Medical and Paediatric Oncology · 10.03.2026
DOI: 10.1055/s-0046-1817797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Medical and Paediatric Oncology, erschienen am 10.03.2026. Verfasst von Sandeep Kukkar und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Pertuzumab + trastuzumab combined with neoadjuvant chemotherapy is a standard approach for treating locally-advanced HER2-positive breast cancer.
Objective
To evaluate pathologic complete response (pCR) rates, safety, and tolerability of the taxane (docetaxel/paclitaxel) +carboplatin + trastuzumab + pertuzumab regimen in a North Indian cohort. Materials and Methods In this retrospective, single-center, observational study, patients with early-stage or locally advanced HER2-positive breast cancer were enrolled. All patients were treated with neoadjuvant taxane + carboplatin + trastuzumab + pertuzumab from April 2018 to September 2024. pCR (ypT0 ypN0) was assessed after surgery. Safety outcomes were recorded based on a number of events and toxicity. Data were summarized using descriptive statistics. Univariate analysis was conducted to identify the predictors of pCR, where a two-sided p < 0.05 was considered statistically significant. Analyses were performed in RStudio.
Results
Forty-one patients (median age: 55 years), with 61% postmenopausal at presentation, were enrolled. The overall pCR rate was 56.1% (23/41), with higher pCR rates in hormone receptor-negative (63.6% vs. 47.4%), T2/T3 (65.4%/60%), and node-negative (100%) tumors. Docetaxel-based regimens showed significantly higher pCR rates than nondocetaxel regimens (74.1% vs. 21.4%, p = 0.002). Although docetaxel-based therapy showed superior efficacy, weekly paclitaxel/carboplatin (AUC2: weekly regimen) demonstrated better tolerability (14.3% dose reductions vs. 29.6% with docetaxel). Grade ≥ 3 adverse events included febrile neutropenia (19.5%), cytopenia (19.5%), and diarrhea (4.9%). Breast-conserving surgery (BCS) was feasible in 61% of patients (n = 25), with 84% (n = 21) among those undergoing BCS achieving pCR.
Conclusion
The taxane (docetaxel/paclitaxel) + carboplatin + trastuzumab + pertuzumab regimen achieved high pCR rates in this cohort, consistent with global data. Weekly paclitaxel-based regimens may improve tolerability, particularly in elderly or comorbidity-burdened populations.
Zitieren
APA
Kukkar, S., Mistry, F., Singla, D., & Watts, V. (2026). Neoadjuvant Taxane/Carboplatin/Trastuzumab/Pertuzumab in Patients with HER2-Positive Early or Locally-Advanced Breast Cancer: A Retrospective, Single-Center, Observational Study. Indian Journal of Medical and Paediatric Oncology. https://doi.org/10.1055/s-0046-1817797
Vancouver
Kukkar S, Mistry F, Singla D, Watts V. Neoadjuvant Taxane/Carboplatin/Trastuzumab/Pertuzumab in Patients with HER2-Positive Early or Locally-Advanced Breast Cancer: A Retrospective, Single-Center, Observational Study. Indian Journal of Medical and Paediatric Oncology. 2026. doi:10.1055/s-0046-1817797
BibTeX
@article{Kukkar2026,
author = {Kukkar, Sandeep and Mistry, Fazila and Singla, Deepak and Watts, Vaibhav},
title = {Neoadjuvant Taxane/Carboplatin/Trastuzumab/Pertuzumab in Patients with HER2-Positive Early or Locally-Advanced Breast Cancer: A Retrospective, Single-Center, Observational Study},
journal = {Indian Journal of Medical and Paediatric Oncology},
year = {2026},
doi = {10.1055/s-0046-1817797}
}
EUVIMED